A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis

International Journal of Pharmacology

Volumn 6, Issue 6, 2010, Pages 826-835

  Nikfar, S ^a,b   Darvish Damavandi, M ^c   Abdollahi, M ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic; Microorganisms; Pouchitis; Probiotic

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN;

ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONSTIPATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; INCIDENCE; INFORMATION RETRIEVAL; LACTOBACILLUS RHAMNOSUS; MELENA; META ANALYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 77958017911     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.826.835     Document Type: Article

References (47)

1. Abdelrazeq, A.S., S.M. Kelly, J.N. Lund and S.H. Leveson, 2005. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis., 7: 182-186.
2. Doherty, G.A., G.C. Bennett, A.S. Cheifetz and A.C. Moss, 2010. Meta-analysis: Targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment. Pharmacol. Ther., 31: 802-809.
3. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig. Dis. Sci., 53: 1278-1284.
4. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2009. Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials. Central Eur. J. Med., 4: 164-170.
5. Fujiwara, S., H. Hashiba, T. Hirota and J.F. Forstner, 1997. Proteinaceous factor(s) in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic Escherichia coli to gangliotetraosylceramide. Applied Environ. Microbiol., 63: 506-512.
6. Furrie, E., S. Macfarlane, A. Kennedy, J.H. Cummings, S.V. Walsh, D.A. O'neil and G.T. Macfarlane, 2005. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 54: 242-249.
7. Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi and D. Matteuzzi, et al, 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebocontrolled trial. Gastroenterology, 119: 305-309.
8. Gionchetti, P., C. Amadini, F. Rizzello, A. Venturi and V. Palmonari et al, 2002. Probiotics-role in inflammatory bowel disease. Dig. Liver Dis., 34: 58-62.
9. Gionchetti, P., F. Rizzello, U. Helwig, A. Venturi and K.M. Lammers et al, 2003. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology, 124: 1202-1209.
10. Gionchetti, P., F. Rizzello, C. Morselli, G. Poggioli and R. Tambasco et al, 2007. High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum, 50: 2075-2082.
11. Gosselink, M.P., W.R. Schouten, L.M. Van-Lieshout, W.C. Hop, J.D. Laman and J.G. Ruseler-van Embden, 2004a. Eradication of pathogenic bacteria and restoration of normal pouch flora: Comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis. Colon Rectum, 47: 1519-1525.
12. Gosselink, M.P., W.R. Schouten, L.M.C. Van-Lieshout, W.C.J. Hop, J.D. Laman and J.G.H. Ruseler-Van Embden, 2004b. Delay of the first onset of pouchitis by oral intake of the probiotic strain lactobacillus rhamnosus GG. Dis. ColonRectum, 47: 876-884.
13. Hart, A.L., K. Lammers, P. Brigidi, B. Vitali and F. Rizzello et al, 2004. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut, 53: 1602-1609.
14. Isaacs, K.L., R.S. Sandler, M. Abreu, M.F. Picco and S.B. Hanauer et al, 2007. Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel. Dis., 13: 1250-1255.
15. Jadad, A., 1998. Randomized Controlled Trials. BMJ Books, London.
16. Kailasapathy, K. and J. Chin, 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol., 78: 80-88.
17. Kruis, W., E. Schutz, P. Fric, B. Fixa, G. Judmaier and M. Stolte, 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 11: 853-858.
18. Kuhbacher, T., S.J. Ott, U. Helwig, T. Mimura and F. Rizzello etal., 2006. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55: 833-841.
19. Kuisma, J., S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin and M. Farkkila, 2003. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment. Pharmacol. Ther., 17: 509-515.
20. Langhendries, J.P., J. Detry and J. Van Hees, 1995. Effect of a fermented infant formula containing viable bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J. Pediatr. Gastroenterol. Nutr.,21: 177-181.
21. Madden, M.V., A.S. Mc-Intyre and R.J. Nicholls, 1994. Metronidazole vs. placebo in chronic unremitting pouchitis. Dig. Dis. Sci., 39: 1193-1196.
22. Mimura, T., F. Rizzello, U. Helwig, G. Poggioli and S. Schreiber et al, 2002. Four-week openlabel trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment. Pharmacol. Ther., 16: 909-917.
23. Mimura, T., F. Rizzello, U. Helwig, G. Poggioli and S. Schreiber et al, 2004. Once daily high dose probiotic therapy (VSL 3) for maintaining remission in recurrent or refractory pouchitis. Gut, 53: 108-114.
24. Nikfar, S., R. Rahimi, F. Rahimi, S. Derakhshani and M. Abdollahi, 2008. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. Dis. Colon Rectum, 51: 1775-1780.
25. Ohge, H., J.K. Furne, J. Springfield, D.A. Rothenberger, R.D. Madoff and M.D. Levitt, 2005. Association between fecal hydrogen sulfide production and pouchitis. Dis. Colon Rectum, 48: 469-475.
26. Pochapin, M., 2000. The effect of probiotics on Clostridium difficile diarrhoea. Am. J. Gastroenterol., 95: 11-13.
27. Pronio, A., C. Montesani, C. Butteroni, S. Vecchione andG. Mumolo et al, 2008. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis., 14: 662-668.
28. Rahimi, R., S. Nikfar, A. Rezaie and M. Abdollahi, 2006. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohns disease. Clin. Ther., 28: 1983-1988.
29. Rahimi, R, S. Nikfar, A. Rezaie and M. Abdollahi, 2007a. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci., 52: 2920-2925.
30. Rahimi, R., S. Nikfar and M. Abdollahi, 2007b. Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med. Sci. Monit, 13: 113-118.
31. Rahimi, R., S. Nikfar and M. Abdollahi, 2007c. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohns disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacofher., 61: 75-80.
32. Rahimi, R, S. Nikfar, F. Rahimi, B. Elahi, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008a. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohns disease. Dig. Dis. Sci., 53: 2524-2531.
33. Rahimi, R., S. Nikfar and A. Rezaie, 2008b. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch. Med. Sci., 4: 185-190.
34. Rezaie, A., S. Nikfar and M. Abdollahi, 2010. The place of antibiotics in management of irritable bowel syndrome: A systematic review and meta-analysis. Arch. Med. Sci., 6: 49-55.
35. Rolfe, R., 2000. The role of probiotic cultures in the control of gastrointestinal health. J. Nutr., 130: 396-402.
36. Ruseler-van Embden, J.G., W.R. Schouten and L.M. Van-Lieshout, 1994. Pouchitis: Result of microbial imbalance?. Gut, 35: 658-664.
37. Sambuelli, A., L. Boerr, S. Negreira, A. Gil and G. Camartino et al, 2002. Budesonide enema in pouchitis-A double-blind, double-dummy, controlled trial. Aliment. Pharmacol. Ther., 16: 27-34.
38. Sandborn, W.J., 1994. Pouchitis following ileal pouch-anal anastomosis: Defnition, pathogenesis and treatment. Gastroenterology, 107: 1856-1860.
39. Sandborn, W.J., W.J. Tremame, K.P. Battsa, J.H. Pemberton and S.F. Phillips, 1994. Pouchitis after ileal pouch-anal anastomosis: A pouchitis dis activity index. Mayo. Clin. Proc, 69: 409-415.
40. Sandborn, W.J., R.S. McLeod and D.P. Jewell, 2000. Pharmacotherapy for induction and maintenance of remission in pouchitis. Cochrane Database Syst. Rev., 2: 1176-1176.
41. Sen, S., M.M. Mullan, T.J. Parker, J.T. Woolner, S.A. Tarry and J.O. Hunter, 2002. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci., 47: 2615-2620.
42. Shen, B., J.P. Achkar, B.A. Lashner, A.H. Ormsby and F.H. Remzi etal, 2001. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis., 7: 301-305.
43. Shen, B., A. Brzezinski, V.W. Fazio, F.H. Remzi and J.P. Achkar et al, 2005. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice. Aliment. Pharmacol. Ther.,22: 721-728.
44. Stochi, L. and J.H. Pemberton, 2001. Pouch and pouchitis. Gastroenteral. Clin. N. Am., 30: 223-241.
45. Ulisse, S., P. Gionchetti, S. Dalo, F.P. Russo and I. Pesce et al, 2001. Expression of cytokines, inducible nitric oxide synthase and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. Am. J. Gastroenterol, 96: 2691-2699.
46. Van-Gossum, A., O. Dewit, E. Louis, G. De-Hertogh and F. Baert et al, 2007. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LAI) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm. Bowel Dis., 13: 135-142.
47. Venturi, A., P. Gionchetti, F. Rizzello, R. Johansson and E. Zucconi et al, 1999. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5-ASA). Aliment. Pharmacol. Ther., 13: 1103-1108.